Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXER1 | Q8TDS5 | 3/20 | 1.00 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.74 |
| ▸ | FAAH | O00519 | 3/20 | 0.69 |
| ▸ | PPARG | P37231 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.68 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.68 |
| ▸ | FABP4 | P15090 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | CASP1 | P29466 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1479725 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL12970667 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL1242004 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL6382220 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL1479722 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL16670813 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL15902619 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL22607964 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL21214020 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 | |
| SCHEMBL198434 | 1.00 | OXER1 (1.00) | OXER1LTB4R2MAPTALOX5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239889-A1 | In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration | GOSSELIN JEAN | 2005-10-27 | — | — | US | claimed |
| US-6093741-A | ANTI-NEOPLASTIC AGENT IN THE PROPHYLAXIS AND TREATMENT OF CANCERS INDUCED BY TUMOR VIRUSES AND IN OTHER NEOPLASIC DISEASES | VIROCELL INC. (CA) | 2000-07-25 | — | — | US | claimed |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | UNIV LELAND STANFORD JUNIOR (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250223580-A1 | PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS | THE BROAD INSTITUTE, INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250051763-A1 | METHODS AND SYSTEMS FOR CONDITIONALLY REGULATING GENE EXPRESSION | FUNDACAO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD FOUNDATION (PT) | 2025-02-13 | — | — | US | disclosed |
| US-20240084335-A1 | CHIMERIC PROTEINS AND METHODS OF REGULATING GENE EXPRESSION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-03-14 | — | — | US | disclosed |
| US-20240044871-A1 | CHIMERIC RECEPTOR POLYPEPTIDE AND METHODS OF ACTIVATION THEREOF | FUNDAÇÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD FOUNDATION (PT) | 2024-02-08 | — | — | US | disclosed |
| CN-109312335-B | Chimeric proteins and methods of modulating gene expression | 斯坦福大学托管董事会 | 2023-10-24 | — | — | CN | disclosed |
| US-20230321146-A1 | CHIMERIC POLYPEPTIDES AND METHODS OF USING THE SAME | FUNDAÇÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD FOUNDATION (PT) | 2023-10-12 | — | — | US | disclosed |
| US-11773411-B2 | Chimeric proteins and methods of regulating gene expression | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20050239889-A1 | In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration | GOSSELIN JEAN | 2005-10-27 | — | — | US | disclosed |
| WO-2004112795-A1 | LTB4 COMPOSITIONS FOR TREATING TRACT INFECTIONS | LTB4 SWEDEN AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| US-20040208882-A1 | Ltb4 as vaccine adjuvant | LTB4 SWEDEN AB (SE) | 2004-10-21 | — | — | US | disclosed |
| US-20040132820-A1 | Agents with leukotriene B4-like antiviral (DNA) and anti-neoplastic activities | GOSSELIN JEAN (CA) | 2004-07-08 | — | — | US | disclosed |
| EP-1401492-A1 | LTB4 AS VACCINE ADJUVANT | Virocell Inc. (CA) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003004054-A1 | LTB4 AS VACCINE ADUVANT | VIROCELL INC. (CA) | 2003-01-16 | — | — | WO | disclosed |
| US-6093741-A | ANTI-NEOPLASTIC AGENT IN THE PROPHYLAXIS AND TREATMENT OF CANCERS INDUCED BY TUMOR VIRUSES AND IN OTHER NEOPLASIC DISEASES | VIROCELL INC. (CA) | 2000-07-25 | — | — | US | disclosed |
| US-5789441-A | Leukotriene B4 as an antiviral and anti-neoplastic agent | VIROCELL INC. (CA) | 1998-08-04 | — | — | US | disclosed |
| US-5725804-A | ALBUMIN PARTICLES STABLE TO RESOLUBILIZATION, POLYOXYETHYLENE GLYCOL, ALCOHOL | HEMOSPHERE, INC. (US) | 1998-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | ADAR, ZFR, SLIRP | OXER1 3091/4885LTB4R2 3626/4885MAPT 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.